December 12, 2016
(Reuters) – Israeli biotech company Bonus Biogroup’s lab-grown, semi-liquid bone graft was successfully injected into the jaws of 11 people to repair bone loss in an early stage clinical trial, it said on Monday. The material, grown in a lab from each patient’s own fat cells, was injected into and filled the voids of the problematic bones. Over a few months it hardened and merged with the existing bone to complete the jaw, it said. The announcement was made in a statement to the Tel Aviv Stock Exchange and Bonus Biogroup is presenting its results at the International Conference on Oral and Maxillofacial Surgery in Spain on Monday.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.